皇冠hg156体育下载地址paul joined nea in 2008. he focuses on later-stage life sciences investments. prior to joining nea, paul worked at mpm capital as a general partner with the mpm bioequities fund, where he specialized in public, pipe and mezzanine-stage life sciences investing. previously, he was a portfolio manager at franklin templeton investments. paul received a bs in biochemistry and cell biology from the university of california at san diego, and holds the chartered financial analyst (cfa) designation. he is a director of allakos (nasdaq: allk), tracon pharmaceuticals (nasdaq: tcon), and trillium therapeutics (nasdasq: tril); he was previously a director of tesaro (nasdaq: tsro) and manages a number of nea’s public healthcare investments.
- October 3, 2018